The most intimate of health data often remains the most elusive. For women navigating fertility, hormonal changes, or recurrent infections, the standard diagnostic tools are episodic, reactive, and often require a clinic visit. Amsterdam-based YON E Health is betting that a small, smart biosensor, worn internally, can shift that paradigm from reactive to continuous and data-driven [TechFundingNews, 2024].
Founded in 2022 by Roswitha Verwer, the startup is developing a device designed to monitor vaginal pH and basal body temperature, key biomarkers for ovulation tracking and signs of bacterial imbalance [FemTech World, 2024]. A €250,000 pre-seed round in 2024, led by PMK-Group with participation from UniPrisma Venture Studio and angel investor Matias Toye, is funding the push toward clinical trials and manufacturing [TechFundingNews, 2024] [Silicon Canals, 2024].
The bet on continuous biomarkers
YON E Health’s core proposition is hardware as a diagnostic wedge. The proposed biosensor would collect data on two primary fronts. Vaginal pH is a well-established indicator for conditions like bacterial vaginosis, while basal body temperature is a cornerstone of natural fertility awareness methods. By automating and continuously logging these metrics, the device aims to provide a longitudinal health picture far richer than a single snapshot from a doctor’s office test strip. The data would be relayed to a companion mobile app, offering users personalized insights and trend analysis [FemTech World, 2024]. This places the company in a small but growing cohort of femtech hardware players moving beyond period tracking apps into regulated medical data collection.
A dual-track go-to-market
Interestingly, the company’s path to users appears to be two-pronged. Alongside the biosensor development, YON E Health operates a direct-to-consumer e-commerce site, YON E Global, selling sustainable organic feminine care products like tampons and liners [FizzyMag, 2024]. This FemCare webshop serves a strategic purpose beyond revenue. It builds an initial community of engaged users interested in holistic vaginal health, creating a potential launchpad and feedback channel for the future biosensor. It also establishes a brand identity focused on safety and body literacy, which is critical for a product asking for profound user trust.
The company’s team, described as a global multidisciplinary group spanning Amsterdam, Budapest, London, and Boston, is led by solo founder Roswitha Verwer [Global Woman Leader, 2026]. Her background prior to YON E was in operations and business development, notably as COO at the Affiliate Business Club [Crunchbase Person Profile, 2026]. While the team brings international perspective, the public record does not yet show prior medical device regulatory experience, a key capability for the road ahead.
The long road to a regulated device
For all its ambition, YON E Health is at the very beginning of a difficult journey. The company’s current status, pre-clinical trials and without a live product, means the core technical and clinical validation work lies entirely ahead. The €250,000 pre-seed is a start, but bringing a novel intimate biosensor to market involves significant capital for safety studies, regulatory submissions (likely CE marking in Europe and/or FDA clearance), and scalable manufacturing.
- Clinical validation. The funding is earmarked for trials, but no timeline or protocol details are public. Proving the device’s accuracy, safety, and clinical utility for detecting conditions like infections will be the paramount hurdle [TechFundingNews, 2024].
- Regulatory pathway. Navigating medical device classification for a continuous internal monitor is complex. The startup will need to demonstrate substantial equivalence or novel efficacy, a process measured in years, not months.
- User adoption. Overcoming the intimacy barrier for continuous internal wear requires exceptional comfort, discreet design, and clear communicated value. Success depends on translating raw pH and temperature data into actionable, trustworthy health guidance.
Competition, while not named in sources, looms from both sides. Established fertility tech companies like Ava and Mira offer external wearable sensors and hormone analyzers. Meanwhile, large medtech firms have deep expertise in intravaginal devices for other indications. YON E Health’s differentiation rests on combining these two biomarker streams into a single, dedicated intimate health device.
The patient population and today’s standard of care
The target user is a woman dealing with specific, often frustrating health journeys. This includes those struggling with unexplained infertility who are charting basal body temperature manually, or individuals plagued by recurrent bacterial vaginosis who lack tools to understand their personal pH patterns. The standard of care today is fragmented. For fertility, it involves manual temperature logging with basal thermometers and intermittent ovulation predictor kits. For vaginal infections, it typically requires symptomatic presentation to a clinician for a speculum exam and lab test, a process that is reactive, sometimes uncomfortable, and can delay treatment. YON E Health’s vision is to provide a continuous, at-home data stream that could empower earlier conversations with healthcare providers and more personalized management of these conditions.
Sources
- [TechFundingNews, 2024] YON E Health scoops €250K to reimagine vaginal health and fertility | https://techfundingnews.com/yon-e-health-vaginal-fertility-biosensors-funding/
- [FemTech World, 2024] YON E Health raises €250k for its vaginal health device | https://www.femtechworld.co.uk/entrepreneur/yon-e-health-raises-e250k-for-its-vaginal-health-device-ftsu26/
- [FizzyMag, 2024] Empowering Women's Health: An Interview with YON E Global | https://fizzymag.com/articles/yon-e-global-womens-health-interview
- [Silicon Canals, 2024] Amsterdam’s women-led femtech startup YON E Health secures funding | https://siliconcanals.com/yon-e-health-secures-funding/
- [Global Woman Leader, 2026] Dutch Femtech Startup YON E Health Raises 250K Euro | https://www.globalwomanleader.com/news/dutch-femtech-startup-yon-e-health-raises-250k-euro-nwid-5229.html
- [Crunchbase Person Profile, 2026] Roswitha Verwer - Founder, CEO and CBO @ YON E Global | https://www.crunchbase.com/person/roswitha-verwer